# US 2004/0081618 A1 · Method of screening physiologically active substance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0081618 A1
- Document ID: US20040081618A1
- Status: Published application
- Kind: A1
- Application number: 10/398,224
- Filed: 2003-04-03
- Published: 2004-04-29
- Earliest claimed: 2000-10-03
- Inventors: Tatsuji Enoki; Shusaku Yamashita; Masatomo Rokushima; Junichi Mineno; Hiroaki Sagawa; Ikunoshin Kato
- Web page: https://patentgrep.com/patent/US20040081618A1

## CPC

- G01N 33/5088: {of vertebrates}
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a method of screening a biologically active substance or a candidate substance for a biologically active substance, possessing an activity for controlling gene expression to the same extent to that of DGE; a gene controlling agent which is effective for maintaining homeostasis in a living body, for instance, purposed for mitigation or prevention of stress; and a method of controlling a gene.

## Claims

### Claim 1

A method of screening a biologically active substance, characterized in that the method comprises the steps of:
(1) loading to a living body either 1) a test substance or 2) a compound of the following (i):
(i) at least one compound selected from the group consisting of a compound represented by the following formula (I):
3
wherein X and Y are H or CH2OH, with proviso that when X is CH2OH, Y is H,
and when X is H, Y is CH2OH,
a derivative thereof and a salt thereof; and/or
a compound of the following (ii):
(ii) at least one compound selected from the group consisting of 3,6-anhydrogalactose represented by the following formula (II):
4
an aldehyde thereof, a hydrate thereof, and a 2-O-methylated product and a 2-O-sulfated product of the foregoing compounds; and/or at least one compound selected from the group consisting of soluble saccharide compounds having said compound at reducing end;
(2) determining an expression level of a gene in the living body of said (1), and comparing resulting values between a case where 1) is loaded and a case where 2) is loaded; and
(3) selecting a test substance which causes a change in an expression level of at least one gene to substantially the same extent as a change where 2) is loaded.

### Claim 2

A method of screening a biologically active substance, characterized in that the method comprises the steps of:
(1) loading a test substance to a living body;
(2) determining an expression level of a gene in the living body of said (1) and an expression level of a gene in the living body without the loading, and comparing resulting values therebetween; and
(3) selecting a test substance which decreases an expression level of at least one gene selected from the following Group A, Group C, Group E and Group F, and/or increases an expression level of at least one gene selected from the following Group B, Group D and Group G:
Group A:
Bone morphogenetic protein-6 [BMP-6 (GenBank Accession No. NM—001718)] gene,
Chemokine receptor-1 [CCR-1 (GenBank Accession No. NM—001295)] gene,
Hepatocyte growth factor [HGF (GenBank Accession No. X16323)] gene,
Intercellular adhesion molecule-1 [ICAM-1 (GenBank Accession No. NM—000201)] gene,
Interleukin-1β [IL-1β (GenBank Accession No. X02532)] gene,
Interleukin-16 [IL-16 (GenBank Accession No. M90391)] gene,
Leukemia inhibitory factor [LIF (GenBank Accession No. NM—002309)] gene,
Osteopontin [Osteopontin (GenBank Accession No. NM—000582)] gene,
Tumor necrosis factor-α [TNF-α (GenBank Accession No. X02910)] gene,
Neuropilin-1 [Neuropilin-1 (GenBank Accession No. NM—003873)] gene,
signal transducer and activator of transcription 6 [STAT6 (GenBank Accession No. AF067575)] gene, and
Gene containing Homo Sapiens cDNA: FLJ22298 fis, clone HRC04637 (GenBank Accession No. AK025951),
Group B:
Heme oxygenase-1 [HO-1 (GenBank Accession No. NM—002133)] gene,
Thioredoxin reductase-1 (GenBank Accession No. AF106697) gene,
putative translation initiation factor [SUIL (GenBank Accession No. AF083441)] gene, and
Homo sapiens hypothetical protein [HSPCO14 (GenBank Accession No. NM—015932)] gene;
Group C:
N-myc downstream regulated gene 1 [NDRG1 (GenBank Accession No. NM—006096)] gene,
adenosine deaminase, RNA specific [ADAR (GenBank Accession No. NM—015841)] gene,
splicing factor 3b, subunit2 [SF3B2 (GenBank Accession No. NM—006842)] gene,
interleukin enhancer binding factor 3 [ILF3 (GenBank Accession No. NM—004516)] gene,
valyl-tRNA synthetase 2 [VARS2 (GenBank Accession No. NM—006295)] gene, and
Gene containing the nucleotide sequence shown in SEQ ID NO: 12 of Sequence Listing;
Group D:
eukaryotic translation elongation factor 1 alpha 1 [EEF1A1 (GenBank Accession No. NM—001402)] gene,
ribosomal protein L17 [RPL17 (GenBank Accession No. NM—000985)] gene,
ribosomal protein L24 [RPL24 (GenBank Accession No. NM—000986)] gene,
splicing factor, arginine/serine-rich 2 [SFRS2 (GenBank Accession No. NM—003016)] gene,
tumor protein, translationally-controlled 1 [TPT1 (GenBank Accession No. NM—003295)] gene,
ubiquinol-cytochrome c reductase binding protein [UQCRB (GenBank Accession No. NM—006294)] gene,
ribosomal protein S15a [RPS15A (GenBank Accession No. NM—001019)] gene, and
ribosomal protein L27 [RPL27 (GenBank Accession No. NM—000988)] gene;
Group E:
Interleukin-2 receptor α [IL2RA (GenBank Accession No. X01057)] gene,
Interleukin-6 [IL6 (GenBank Accession No. X04430)] gene,
CD166 (GenBank Accession No. Y10183) gene,
Interferon regulatory factor-1 [IRF1 (GenBank Accession No. X14454)] gene,
Interleukin-15 receptor α [IL1SRA (GenBank Accession No. U31628)] gene,
Nuclear factor kappa-b p105 Subunit [NFKB1 (GenBank Accession No. M58603)] gene,
Caspase-1 [CASP1 (GenBank Accession No. M87507)] gene,
Interleukin-1β [IL1B (GenBank Accession No. M15330)] gene,
Tumor necrosis factor-α [TNF-α (GenBank Accession No. X02910)] gene,
Gro1 oncogene [GRO1 (GenBank Accession No. X54489)] gene,
Interleukin-1α [IL1A (GenBank Accession No. M28983)] gene,
Inhibin βA [INHBA (GenBank Accession No. J03634)] gene,
Interleukin-7 receptor [IL7R (GenBank Accession No. M29696)] gene,
Precursor B cell colony enhancing factor [PBEF (GenBank Accession No. U02020)] gene,
Liver and activation regulated chemokine [LARC (GenBank Accession No. U64197)] gene, and
Interleukin-8 [IL8 (GenBank Accession No. M26383)] gene;
Group F:
Colony-stimulating factor-1 receptor [CSF1R (GenBank Accession No. X03663)] gene,
Chemokine (C-X-C motif) receptor-4 [CXCR4 (GenBank Accession No. AF147204)] gene, and
Endoglin [ENG (GenBank Accession No. NM—000118)] gene; and
Group G:
Heme oxygenase-1 [HMOX1 (GenBank Accession No. Z82244)] gene.

### Claim 3 (depends on 2)

A method of screening a biologically active substance, characterized in that the method comprises the steps of:
(1) loading stress to a living body, and loading a test substance with stress to a living body, respectively;
(2) determining each of expression levels of a gene in the living body of said (1) and in a normal living body without any of the loading; and
(3) comparing the expression levels of a gene obtained in said (2) between the living body of said (1) and the normal living body, and selecting a test substance showing at least one gene expression pattern selected from the gene expression patterns of the followings (a) to (g):
(a) an expression level of at least one gene selected from Group A as defined in claim 2 increases when stress is loaded to a living body, and decreases when a test substance and stress are loaded to a living body, as compared to that of the normal living body;
(b) an expression level of at least one gene selected from Group B as defined in claim 2 increases when stress is loaded to a living body, and further increases when a test substance and stress are loaded to a living body, as compared to that of the normal living body;
(c) an expression level of at least one gene selected from Group C as defined in claim 2 decreases when stress is loaded to a living body, and further decreases when a test substance and stress are loaded to a living body, as compared to that of the normal living body;
(d) an expression level of at least one gene selected from Group D as defined in claim 2 decreases when stress is loaded to a living body, and increases when a test substance and stress are loaded to a living body, as compared to that of the normal living body;
(e) an expression level of at least one gene selected from Group E as defined in claim 2 increases when stress is loaded to a living body, and decreases when a test substance and stress are loaded to a living body, as compared to that of the normal living body;
(f) an expression level of at least one gene selected from Group F as defined in claim 2 is the same extent as that of the normal living body when stress is loaded to a living body, and decreases when a test substance and stress are loaded to a living body, as compared to that of the normal living body; and
(g) an expression level of at least one gene selected from Group G as defined in claim 2 is the same extent as that of the normal living body when stress is loaded to a living body, and increases when a test substance and stress are loaded to a living body, as compared to that of the normal living body.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the stress is a treatment with phorbol myristate acetate, and wherein the gene expression pattern is selected from the gene expression patterns of said (a) to (d).

### Claim 5 (depends on 3)

The method according to claim 3, wherein the stress is a treatment with lipopolysaccharide, and wherein the gene expression pattern is selected from the gene expression patterns of said (e) to (g).

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method according to any one of claims 1 to 5, wherein the living body is an organism individual or a cultured cell.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method according to any one of claims 1 to 6, wherein the expression level of a gene is determined by an amount of mRNA transcribed from the gene.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the expression level of a gene is determined by hybridization method using a DNA array.

### Claim 9 (depends on 2, 8)

A DNA array usable for the method of claim 8, characterized in that at least two genes selected from the genes of Groups A to G as defined in claim 2 or fragments thereof are immobilized on a support at a given position.

### Claim 10 (depends on 2)

A gene controlling agent characterized in that the gene controlling agent comprises a compound possessing an action of decreasing an expression level of at least one gene selected from Group A, Group C, Group E and Group F as defined in claim 2, and/or increasing an expression level of at least one gene selected from Group B, Group D and Group G as defined in claim 2.

### Claim 11 (depends on 2)

A gene controlling agent characterized in that the gene controlling agent comprises a compound possessing an action of decreasing an expression level of at least one gene selected from Group A, Group C, Group E and Group F as defined in claim 2, and/or increasing an expression level of at least one gene selected from Group B, Group D and Group G as defined in claim 2, in a living body to which stress is loaded.

### Claim 12 (depends on 2)

A gene controlling agent characterized in that the gene controlling agent comprises a compound possessing an action of decreasing an expression level of at least one gene selected from Group A and Group E as defined in claim 2 in a living body to which stress is loaded, wherein the expression level of at least one gene is increased by the stress.

### Claim 13 (depends on 2)

A gene controlling agent characterized in that the gene controlling agent comprises a compound possessing an action of increasing an expression level of at least one gene selected from Group B and Group G as defined in claim 2 in a living body to which stress is loaded, wherein the expression level of at least one gene is increased by the stress.

### Claim 14 (depends on 2)

A gene controlling agent characterized in that the gene controlling agent comprises a compound possessing an action of decreasing an expression level of at least one gene selected from Group C and Group F as defined in claim 2 in a living body to which stress is loaded, wherein the expression level of at least one gene is decreased by the stress.

### Claim 15 (depends on 2)

A gene controlling agent characterized in that the gene controlling agent comprises a compound possessing an action of increasing an expression level of at least one gene selected from Group D as defined in claim 2 in a living body to which stress is loaded, wherein the expression level of at least one gene is decreased by the stress.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 15)

The gene controlling agent according to any one of claims 10 to 15, wherein the compound is a substance obtained by the method of any one of claims 1 to 8.

### Claim 17 (depends on 10, 11, 12, 13, 14, 15, 16)

The gene controlling agent according to any one of claims 10 to 16, wherein the gene control agent is purposed for mitigating or preventing stress.

### Claim 18 (depends on 1, 2)

A method of controlling a gene characterized by administering to a living body either at least one compound selected from the group consisting of compounds of (i) and (ii) as defined in claim 1 and a compound possessing an activity for controlling gene expression to substantially the same extent as that of said compounds for at least one gene, or a composition comprising the compound, thereby decreasing an expression level of at least one gene selected from Group A, Group C, Group E and Group F, and/or increasing an expression level of at least one gene selected from Group B, Group D and Group G, wherein Groups A to G are as defined in claim 2.

### Claim 19 (depends on 1, 2)

A method of controlling a gene characterized by administering to a living body to which stress is loaded either at least one compound selected from the group consisting of compounds of (i) and (ii) as defined in claim 1 and a compound possessing an activity for controlling gene expression to substantially the same extent as that of said compounds for at least one gene, or a composition comprising the compound, thereby decreasing an expression level of at least one gene selected from Group A, Group C, Group E and Group F, and/or increasing an expression level of at least one gene selected from Group B, Group D and Group G, wherein Groups A to G are as defined in claim 2.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 18, 19)

The method according to claim 18 or 19, wherein the compound possessing an activity for controlling gene expression to substantially the same extent as that of compounds of (i) and (ii) in claim 1 for at least one gene is a substance obtained by the method of any one of claims 1 to 8.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

A substance obtainable by the method of any one of claims 1 to 8.

### Claim 22 (depends on 21)

The substance according to claim 21, which is a substance derived from a plant, a substance derived from Basidiomycetes, or a derivative thereof.

### Claim 23 (depends on 21, 22)

The substance according to claim 21 or 22, which is a polysaccharide, a degradation product thereof, or a derivative thereof.
